Products
Online Inquiry
SR-318
Cat. No.:
OB0225WX-2108
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
SR-318 is a highly selective p38 MAPK inhibitor, demonstrating IC50 values of 5 nM for p38alpha and 32 nM for p38beta, while exhibiting 6.11 μM potency against the alpha/beta complex.
Synonym:
2413286-32-3; 5-amino-N-[[4-(3-cyclohexylpropylcarbamoyl)phenyl]methyl]-1-phenylpyrazole-4-carboxamide; 5-azanyl-~{N}-[[4-(3-cyclohexylpropylcarbamoyl)phenyl]methyl]-1-phenyl-pyrazole-4-carboxamide; 5-Amino-N-(4-(3-cyclohexylpropylcarbamoyl)benzyl)-1-phenyl-1H-pyrazole-4-carboxamide; 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl-; LBE
CAS No.:
2413286-32-3
Compound CID:
139030333
Formula:
C27H33N5O2
Formula Weight:
459.58
Specification
Targets&IC50:
TNF-α: 283 nM; p38α: 5 nM; p38α/β: 6.11 μM; p38β: 32 nM
Relative Density:
1.24 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SR-318 is employed in biochemical research as a specialized chemical probe to examine the targeted inhibition of specific metabolic enzymes and their role in cellular homeostasis.
Library Information
Target:
p38 MAPK; TNF
Receptor:
p38 MAPK; TNF-α
Pathways:
Apoptosis; MAPK
Plate Number:
AOCL-28
Plate Location:
a3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
125 mg/mL; 271.99 mM
